Alkermes (ALKS) Competitors

Biogen (NASDAQ:BIIB) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Which has more volatility & risk, BIIB or ALKS?

Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Does the MarketBeat Community prefer BIIB or ALKS?

Biogen received 1118 more outperform votes than Alkermes when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 70.18% of users gave Alkermes an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%
Alkermes	Outperform Votes 706 70.18%	Underperform Votes 300 29.82%

Does the media refer more to BIIB or ALKS?

In the previous week, Alkermes had 1 more articles in the media than Biogen. MarketBeat recorded 9 mentions for Alkermes and 8 mentions for Biogen. Biogen's average media sentiment score of 1.28 beat Alkermes' score of 0.86 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BIIB or ALKS?

Biogen currently has a consensus target price of $191.30, indicating a potential upside of 43.77%. Alkermes has a consensus target price of $38.85, indicating a potential upside of 24.51%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.77

Do insiders & institutionals believe in BIIB or ALKS?

87.9% of Biogen shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 4.4% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is BIIB or ALKS more profitable?

Alkermes has a net margin of 23.57% compared to Biogen's net margin of 16.87%. Alkermes' return on equity of 30.80% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Alkermes	23.57%	30.80%	19.09%

Which has higher valuation and earnings, BIIB or ALKS?

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.82B	1.99	$1.63B	$10.13	13.14
Alkermes	$1.51B	3.40	$367.07M	$2.09	14.93

Summary

Alkermes beats Biogen on 11 of the 19 factors compared between the two stocks.